Aethlon Medical Inc
NASDAQ:AEMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eutelsat Communications SA
OTC:ETCMY
|
FR |
Aethlon Medical Inc
Other
Aethlon Medical Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Aethlon Medical Inc
NASDAQ:AEMD
|
Other
-$1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other
-$186m
|
CAGR 3-Years
26%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other
-$237.5m
|
CAGR 3-Years
-304%
|
CAGR 5-Years
-188%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Other
-$182m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other
-$82m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-17%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other
-$419.1m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-37%
|
|
Aethlon Medical Inc
Glance View
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
See Also
What is Aethlon Medical Inc's Other?
Other
-1.2m
USD
Based on the financial report for Dec 31, 2025, Aethlon Medical Inc's Other amounts to -1.2m USD.